Lantheus extends moly contract with Nordion

by Brendon Nafziger, DOTmed News Associate Editor | January 05, 2011

Lantheus Medical Imaging said Wednesday it extended its contract with medical isotope supplier Nordion through 2013.

Originally, the deal to supply N. Billerica, Mass.-based Lantheus with molybdenum-99 was set to expire at the end of July.

Lantheus CEO and president Don Kiepert said the arrangement with Ottawa-based Nordion follows the company's policy of diversifying sourcing of Mo-99, which is only produced by a handful of reactors around the world. Last year, the shutdown of two aging reactors in the Netherlands and Canada for repairs led to global shortages of the isotope.

You don’t have to invest heavily in CT technology to achieve your Coronary CTA goals

Fast-moving cardiac structures have a big impact on imaging. Fujifilm’s SCENARIA View premium performance CT brings solutions to address motion in Coronary CTA while delivering unique dose saving and workflow increasing benefits.

Mo-99 is the parent isotope of technetium-99m, widely used in nuclear medicine scans of the heart. Lantheus sells generators that milk Mo-99 into its daughter isotope.